Matt O'Brien
Stock Analyst at Piper Sandler
(2.24)
# 2,752
Out of 5,147 analysts
198
Total ratings
43.64%
Success rate
-4.6%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $50 → $28 | $22.69 | +23.40% | 6 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Overweight | $140 → $160 | $145.26 | +10.15% | 14 | Feb 25, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $14 → $21 | $25.30 | -17.00% | 10 | Feb 20, 2026 | |
| GMED Globus Medical | Reiterates: Overweight | $90 → $115 | $95.46 | +20.47% | 13 | Jan 8, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Overweight | $27 → $30 | $23.28 | +28.87% | 2 | Dec 12, 2025 | |
| TELA TELA Bio | Reiterates: Neutral | $2 → $1.25 | $0.87 | +43.99% | 7 | Nov 14, 2025 | |
| SI Shoulder Innovations | Reiterates: Overweight | $18 | $13.56 | +32.74% | 2 | Nov 12, 2025 | |
| CNMD CONMED | Maintains: Overweight | $68 → $55 | $46.00 | +19.57% | 14 | Nov 6, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $75 | $73.43 | +2.14% | 13 | Oct 31, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $20 → $25 | $13.62 | +83.55% | 4 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $26 → $32 | $12.63 | +153.37% | 2 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $155 → $82 | $86.68 | -5.40% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $19.17 | +14.76% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $14.57 | +23.54% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $8.16 | +47.06% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $120.40 | +37.04% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $5.16 | -32.17% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $122.06 | +14.70% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $246.61 | +25.70% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $344.39 | -4.18% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $31.26 | +59.95% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $19.90 | -19.60% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $76.85 | +49.64% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $5.03 | +138.57% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $387.46 | +8.40% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $97.66 | -7.84% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $15.52 | +61.08% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.12 | +169.06% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.27 | +37.61% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $98.44 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.38 | +242.47% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $83.67 | +29.97% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $20.37 | +292.73% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.77 | +151.57% | 1 | Jun 24, 2020 |
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Overweight
Price Target: $50 → $28
Current: $22.69
Upside: +23.40%
TransMedics Group
Feb 25, 2026
Maintains: Overweight
Price Target: $140 → $160
Current: $145.26
Upside: +10.15%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $14 → $21
Current: $25.30
Upside: -17.00%
Globus Medical
Jan 8, 2026
Reiterates: Overweight
Price Target: $90 → $115
Current: $95.46
Upside: +20.47%
Kestra Medical Technologies
Dec 12, 2025
Maintains: Overweight
Price Target: $27 → $30
Current: $23.28
Upside: +28.87%
TELA Bio
Nov 14, 2025
Reiterates: Neutral
Price Target: $2 → $1.25
Current: $0.87
Upside: +43.99%
Shoulder Innovations
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $13.56
Upside: +32.74%
CONMED
Nov 6, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $46.00
Upside: +19.57%
DexCom
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $73.43
Upside: +2.14%
Alphatec Holdings
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $13.62
Upside: +83.55%
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $12.63
Upside: +153.37%
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $86.68
Upside: -5.40%
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $19.17
Upside: +14.76%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $14.57
Upside: +23.54%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $8.16
Upside: +47.06%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $120.40
Upside: +37.04%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $5.16
Upside: -32.17%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $122.06
Upside: +14.70%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $246.61
Upside: +25.70%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $344.39
Upside: -4.18%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $31.26
Upside: +59.95%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $19.90
Upside: -19.60%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $76.85
Upside: +49.64%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $5.03
Upside: +138.57%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $387.46
Upside: +8.40%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $97.66
Upside: -7.84%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $15.52
Upside: +61.08%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.12
Upside: +169.06%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.27
Upside: +37.61%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $98.44
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.38
Upside: +242.47%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $83.67
Upside: +29.97%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $20.37
Upside: +292.73%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.77
Upside: +151.57%